Free tool
FAERS Monitor: Spiriva
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021395 or its brand name (Spiriva, Tiotropium Bromide). Reports on generic versions are filed under their own applications.
Reports
136,778
Serious
68,481
50% of reports
Hospitalization
39,539
Death reported
9,823
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- incorrect route of drug administration23,320
- dyspnoea22,675
- asthma11,105
- drug ineffective9,516
- cough8,787
- pneumonia8,561
- wheezing6,931
- chronic obstructive pulmonary disease6,316
- product quality issue5,982
- fatigue5,465
- off label use4,786
- malaise4,629
- nausea4,116
- fall3,985
- headache3,955
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,291 |
| 2005 | 2,059 |
| 2006 | 1,844 |
| 2007 | 2,925 |
| 2008 | 5,102 |
| 2009 | 5,565 |
| 2010 | 6,479 |
| 2011 | 6,242 |
| 2012 | 7,661 |
| 2013 | 9,766 |
| 2014 | 10,467 |
| 2015 | 12,811 |
| 2016 | 12,445 |
| 2017 | 8,460 |
| 2018 | 7,430 |
| 2019 | 7,135 |
| 2020 | 6,729 |
| 2021 | 6,632 |
| 2022 | 4,487 |
| 2023 | 3,547 |
| 2024 | 3,258 |
| 2025 | 2,707 |
| 2026 | 1,736 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,917,381 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| incorrect route of drug administrationSignal | 23,320 | 286.3 | 280.3 | 2,312,131 |
| chronic obstructive pulmonary diseaseSignal | 6,316 | 21.0 | 20.5 | 106,204 |
| wheezingSignal | 6,931 | 20.2 | 19.7 | 112,117 |
| asthmaSignal | 11,105 | 16.6 | 16.3 | 148,062 |
| product quality issueSignal | 5,982 | 7.0 | 6.9 | 29,813 |
| dyspnoeaSignal | 22,675 | 6.4 | 6.3 | 101,361 |
| coughSignal | 8,787 | 4.9 | 4.8 | 27,120 |
| pneumoniaSignal | 8,561 | 4.1 | 4.1 | 20,231 |
| fall | 3,985 | 1.9 | 1.8 | 1,565 |
| malaise | 4,629 | 1.6 | 1.6 | 1,137 |
| drug ineffective | 9,516 | 1.1 | 1.1 | 112 |
| fatigue | 5,465 | 1.1 | 1.1 | 33 |
| headache | 3,955 | 1.0 | 0.9 | 4 |
| off label use | 4,786 | 0.8 | 0.8 | 152 |
| nausea | 4,116 | 0.8 | 0.8 | 216 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.